Gastrointestinal stromal tumor (GIST) is a type of KIT-driven cancer. KIT gene mutations are found in approximately 80% of GISTs, and most of these mutations occur in exon 9 and exon 11. Imatinib has been successfully used as a first-line treatment for advanced GIST, with a significant improvement in progression-free survival (PFS) and overall survival. However, disease progression might develop due to primary or secondary resistance to imatinib. Sunitinib and regorafenib have been approved as second-and thirdline treatments for advanced GIST patients, with median PFS values of 6.8 and 4.8 months, respectively. However, these relatively modest improvements in PFS underscore the need for more effective KIT inhibitors. BPR1J373 is a multitargeted kinase inhibitor that has been shown to inhibit the proliferation of KIT-driven acute myeloid leukemia cells in vitro and in vivo. In this study, we found that BPR1J373 inhibited proliferation and induced apoptosis by targeting KIT in GIST cells with KIT gene mutations. BPR1J373 also induced cell cycle arrest and senescent change in KIT-mutant GIST48 cells, probably by targeting aurora kinase A. In the KIT-null COS-1 cell-based system, BPR1J373 effectively inhibited KIT with single or double mutations of KIT developed in GIST. The antiproliferative effect was also consistently evident in GIST430 tumor-grafted mice. The results suggest that BPR1J373 could be a potential anticancer drug for GIST and deserves further investigation for clinical applications.
| INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are neoplasms arising from mesenchymal tissue of the gastrointestinal tract and are thought to originate from progenitors of the interstitial cells of Cajal. The stomach and small intestine are the most common sites of GISTs, and approximately 60% of GISTs can be cured by surgery. However, approximately 40% of patients initially diagnosed with localized GISTs develop metastasis. 1 Gastrointestinal stromal tumors are a type of KIT-driven cancer, which was found by Hirota et al 2 in 1998 to harbor mutations in the KIT oncogene. Gastrointestinal stromal tumors are usually unresponsive to conventional chemotherapy.
Imatinib, which targets platelet-derived growth factor receptor (PDGFR) and Bcr-Abl, 3, 4 was shown to induce a good response in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia patients in phase I/II studies and was approved as a first-line treatment for both diseases. [5] [6] [7] [8] In 2000,
Heinrich et al 9 showed that this drug could inhibit the phosphorylation of KIT in KIT-mutated HMC-1 cells and effectively inhibit the proliferation of HMC-1 cells. Imatinib was also shown to induce a notably good response in an advanced GIST patient who had failed multiple treatments. 10 In addition, imatinib treatment achieved a disease control rate of 81.6% for advanced GIST, leading to significant improvement in progression-free survival (PFS) and overall survival (OS) in the initial phase II study. 11 Therefore, imatinib has become the first-line treatment for advanced GIST with a long-term median OS of 51-57 months in phase II and phase III trials. 12, 13 Disease progression of GIST might develop further due to either primary or secondary resistance to imatinib. 14, 15 KIT mutations are found in approximately 80% of GISTs, and mutations in exons 9 and 11 are the most frequent at diagnosis. 16, 17 Patients with exon 9 mutations have a lower response rate to imatinib and inferior PFS and OS when compared with patients with primary exon 11 mutations. [16] [17] [18] [19] [20] Secondary mutations of KIT occur in exons 13, 14, 17, or 18, which might indicate a clonal selection after long-term imatinib therapy, and develop more frequently in patients with primary exon 11 mutations. [21] [22] [23] For imatinib-resistant GIST patients, sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), was shown to improve PFS and OS and is approved as a second-line treatment for advanced GIST patients after treatment failure or intolerance to imatinib. 24 Considering the genotype of GIST and response to sunitinib, patients who harbor primary exon 9 mutations and WT KIT have longer median PFS and OS than patients with exon 11 mutations. Moreover, sunitinib showed poorer response in patients with secondary mutations in exons 17/18 than in exons 13/14. 24 In addition, regorafenib was approved in 2013 as the third-line treatment for GIST patients who failed to respond, or were intolerant to, treatment with imatinib and sunitinib, according to results from a phase III study. 25 The median PFS was 4.8 months compared with 0.9 month for the placebo control group. Therefore, for refractory GIST, development and identification of novel agents are mandatory.
BPR1J373, a 5-phenylthiazol-2-ylamine-pyriminide derivative, is a multitargeted kinase inhibitor with potent inhibitory activity against fms like tyrosine kinase 3, KIT, vascular endothelial growth factor receptor (VEGFR), Aurora A, Aurora B, PDGFRα, PDGFRβ, reannanged during transfection, and sarcoma in preliminary kinase profiling. The structure of BPR1J373 was shown previously. 26 The antikinase profile of BPR1J373 is presented in Figure S1 . BPR1J373
has been shown to inhibit proliferation of KIT-driven acute myeloid leukemia cells in vitro and in vivo. 26 In this study, we report the effectiveness and mechanisms by which BPR1J373 inhibits the proliferation of KIT-mutant GIST cells in vitro and in vivo.
| MATERIALS AND METHODS

| Cell lines and reagents
The GIST cell lines GIST882, GIST48, GIST430, GIST-T1, GIST62, GIST48B, and COS-1 were selected for the current study. All cells were cultured in incubators maintained at 37°C and 5% CO 2 .
GIST882 and GIST62 were cultured in RPMI-1640 supplemented 
| Apoptosis assay
Gastrointestinal stromal tumor cell lines GIST882, GIST430, and GIST48 were cultured in 6-well plates and treated with or without 2× IC 50 and 1 μmol/L BPR1J373. The cells were collected at prespecified times, stained with annexin V-phycoerythrin and propidium iodide, and analyzed by BD FACSCalibur (Becton Dickinson, Franklin
Lakes, NJ, USA). 
| Cell proliferation assay
| Western blot analysis
The GIST cells were treated with 1 μmol/L imatinib, sunitinib, nilotinib, 
| KIT-mutant transfections
Plasmids containing KIT mutations were produced as described previously. 27 . The doses of sunitinib and regorafenib were chosen according to efficacy studies in mouse xenograft models. [28] [29] [30] [31] [32] The maximum tolerated dose of BPR1J373 was 75 mg/kg, and we chose 50 mg/kg in this study for safety considerations. The drugs were dissolved in 20%
(2-hydroxypropyl)-β-cyclodextrin (Sigma) for oral feeding. The tumor volume was measured three times per week for up to 16 days using the following formula: length (mm) × width 2 (mm 2 ) × (π/6). 33 Body weight was also measured at the same time as the tumor measurement.
| BPR1J373 inhibited the proliferation of
KIT-mutant GIST cells
Gastrointestinal stromal tumor cell lines, including KIT-dependent GIST882, GIST48, and GIST430 and KIT-null GIST48B and GIST62, were treated with BPR1J373 and screened for the inhibitory effect of BPR1J373 on cell proliferation using methylene blue staining. The BPR1J373 IC 50 values for 2× doubling time were 14.8, 3.9, 4.5, BPR1J373, imatinib was relatively active against GIST882, sunitinib was active against GIST882 and GIST430, and nilotinib had the greatest activity against GIST48. Regorafenib was less effective than sunitinib and nilotinib in suppressing the growth of GIST430 and GIST48, respectively. Another imatinib-sensitive GIST cell line, GIST-T1, was also evaluated for an antiproliferative effect by the above agents. BPR1J373, sunitinib, and nilotinib exerted the best antiproliferative effects, as shown in Figure S2A .
| BPR1J373 effectively suppressed KIT phosphorylation and downstream signaling in GIST cell lines
Because KIT is a driving oncogene responsible for the cell growth of GIST cells with KIT mutations, activation of KIT was determined by its phosphorylation status in GIST882, GIST430, and GIST48 cells. induction of apoptosis. However, the percentage of annexin-V-positive cells was much lower than the inhibitory proportion of BPR1J373-treated GIST48 and GIST430 cells ( Figure 1A ). This result suggests that antiproliferation of GIST48 and GIST430 by BPR1J373 might be mediated by both apoptotic-and non-apoptotic-dependent mechanisms.
| Cell cycle arrest and cellular senescence caused by BPR1J373
To investigate the potential non-apoptotic events in GIST48 and Figure 4B ). In addition, because BPR1J373 was shown to have an inhibitory effect on the activation of Aurora kinase, we examined the expression of Aurora kinase A and B and found that the phosphorylation of Aurora kinase A could be suppressed by BPR1J373 in GIST48 cells ( Figure 4B ). Thus, data suggest that BPR1J373-induced senescence in GIST48 cells might be mediated by the inactivation of Aurora kinase A activity.
| BPR1J373 suppressed KIT activation of COS-1 cells with KIT-mutant genes
To determine whether BPR1J373 suppresses KIT phosphorylation for other KIT mutations common in GIST, we transfected COS-1 cells using plasmids with various KIT mutant genes, including single (AY502-503 duplication in exon 9, Δ557-558 deletion in exon 11, exerted the most potent effect on suppression of KIT phosphorylation of these COS-1 transfectants, as shown in Figure 5A . Furthermore, BPR1J373 also showed a remarkable potency in the suppression of KIT activation in COS-1 transfectants with all 4 double mutations, whereas imatinib, sunitinib, nilotinib, and regorafenib showed variable effects on suppression of KIT phosphorylation (Fig- ure 5B). For D816V in exon 17, which is resistant to imatinib, sunitinib, and nilotinib, BPR1J373 still suppressed KIT phosphorylation in a time-dependent manner, whereas the other 3 tyrosine kinase inhibitors did not, as shown previously. The differential inhibitory effect on KIT phosphorylation of commercially available TKIs, including imatinib, sunitinib, nilotinib, dasatinib, and sorafenib, was evident in the in vitro KIT-expressing COS-1 cellbased system. 34 No single drug showed a potent effect targeting all of the common KIT mutations in GIST, including single and double mutations. This result corresponds to the variable responses to these TKIs among advanced GIST patients. In the present study, we revealed the potent antiproliferative effect of BPR1J373 in suppressing the growth of both imatinib-sensitive and imatinib-resistant GIST cell lines. Furthermore, the inhibition of KIT phosphorylation by BPR1J373 in a COS-1 cell-based system was superior to that obtained with other available TKIs for various KIT mutations, including KIT D816V mutation, which is resistant to all available TKIs. In addition to KIT, other targets were shown to contribute to the survival of GIST. Sunitinib was shown to be effective for GIST by targeting KIT and VEGFR. 28 In an in vitro study, sorafenib was shown to be a potential active agent for GIST based on its potent suppression of mutant KIT and PDGFRA. 35 Abrogation of the protective effect of heat shock protein 90 in preventing KIT proteasomemediated degradation is another approach for targeting imatinibresistant KIT-positive GIST and has been evaluated in clinical trials.
Monoclonal antibodies targeting PDGFRA and VEGFR, mTOR inhibitors, and PI3K/AKT inhibitors have also been studied to treat GIST in phase II or III studies in patients with imatinib-resistant GIST. 1, 15, 36, 37 The efficacy of these agents remains to be determined. 
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